ACG 2021: Investigational Oral Microbiome Therapeutic Agent CP101 Effectively Treats Recurrent Clostridioides difficile
The agent is moving forward with phase III research
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.